GENEVA, SWITZERLAND / ACCESSWIRE / /RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the ...

The Company's BLA for pz-cel was previously accepted for Priority Review by the FDA for patients with RDEB. Abeona may be ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

BOSTON--BPGbio received FDA Rare Pediatric Disease Designation for its investigational treatment for Epidermolysis Bullosa ...

Irish actor Colin Farrell recently finished the Dublin Marathon in 4:06:45, and he ran the last 2.5 miles while pushing his ...

However, in recent years he has worked as vice president of Debra UK, helping to raise awareness of epidermolysis bullosa (EB ...

Abeona Therapeutics (ABEO) announced the FDA has accepted for review resubmission of Biologics License Application for prademagene ...

“The EB community is thrilled by this designation, as EB patients and families remain hopeful for more effective treatments,” said Brett Kopelan, Executive Director, DEBRA of America, the largest EB ...

its investigational treatment for epidermolysis bullosa (EB). This designation coincides with EB Awareness Week, observed annually from October 25-31, highlighting the urgent need for innovative ...

This marks the company’s second Rare Pediatric Disease Designation for BPM31510 franchise in the last two months BPM31510T targets mitochondrial machinery to promote wound healing in EB patients ...

Farrell pushed his friend with EB for the last 4 kilometers of the race, each kilometer representing a decade she has lived ...